Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Virtual Tribunal Monastery
Jiangsu HengRui Medicine Co., Ltd.
Indiana University
Thomas Jefferson University
The Christie NHS Foundation Trust
Wake Forest University Health Sciences
University of Leipzig
Keros Therapeutics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
University of Nebraska
Hamad Medical Corporation
Ottawa Hospital Research Institute
Xperiome
Centre Leon Berard
University of Utah
Rutgers, The State University of New Jersey
Children's Mercy Hospital Kansas City
Memorial Sloan Kettering Cancer Center
X4 Pharmaceuticals
Emory University
University of Louisville
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Northwestern University
Memorial Sloan Kettering Cancer Center
Mesoblast, Ltd.
Rabin Medical Center
University of California, San Francisco
Endo Pharmaceuticals